Table III.

T-cell therapy for adenovirus infection after stem cell transplant.

Reference	n	HSCT type	Strategy	End points	Results
Feuchtinger, 2006 (38)	9	MRD, MUD, MMUD, haplo	Treatment (refractory/unresponsive to antiviral drugs)	Safety Efficacy CTL expansion	➢1 case of aggravated pre-existing GvHD ➢AdV-specific T cells detectable in 5/6 patients ➢5/6 patients cleared AdV
Leen, 2006 (11) and Hanley 2013 (15)	34	MRD, MUD, haplo	Prophylaxis	Safety Efficacy CTL expansion	➢No GvHD ➢11/12 patients with AdV cleared the virus ➢Rise in AdV-specific T cells in patients with AdV infection
Leen, 2009 (46)	13	MUD, haplo	Prophylaxis (12) Treatment (1)	Safety Efficacy CTL expansion	➢No GvHD ➢10 patients remained AdV-free ➢2 patients had AdV and cleared after CTL infusion ➢Rise in AdV-specific T cells only in patients with AdV infection
Hanley, 2012 (51)	7	Cord blood	Prophylaxis treatment	Safety Efficacy CTL expansion	➢No de novo GvHD ➢6 patients remained AdV-free ➢1 patient had AdV infection and cleared spontaneously ➢Detectable AdV-specific T cells in patient with AdV infection